Gregory Gene  Freitag net worth and biography

Gregory Freitag Biography and Net Worth

Director of AxoGen

Gregory G. Freitag is the founder of FreiMc LLC, serving as Principal since 2009. Mr. Freitag is also the founder of EmployRx. Inc. Mr. Freitag is currently Chairman at People Serving People, Inc., Director at Chumbo Holdings Corp, Director-Foundation Board at HealthEast Care System LLC, Independent Director at PDS Biotechnology Corp. since 2019, and Independent Director at ZyVersa Therapeutics, Inc. since 2023. Former positions include President & Chief Executive Officer at HTS Biosystems, Inc. from 2000 to 2005, Director, Chief Executive & Financial Officer at LecTec Corp. in 2011, COO, CFO, Director & General Counsel at Quantech Ltd. from 1995 to 2000, Independent Director at Pressure BioSciences, Inc. from 2011 to 2012, Director at PDS Operating Corp., Director-Business Development at Pfizer Health Solutions, Inc. from 2006 to 2009, and Director at Axogen, Inc. from 2021 to 2024.

Education includes a graduate degree from The University of Chicago, conferred in 1987, and an undergraduate degree from Macalester College, conferred in 1984.

What is Gregory Gene Freitag's net worth?

The estimated net worth of Gregory Gene Freitag is at least $2.88 million as of March 7th, 2024. Freitag owns 271,594 shares of AxoGen stock worth more than $2,876,452 as of June 9th. This net worth evaluation does not reflect any other assets that Freitag may own. Learn More about Gregory Gene Freitag's net worth.

How do I contact Gregory Gene Freitag?

The corporate mailing address for Freitag and other AxoGen executives is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. AxoGen can also be reached via phone at (386) 462-6800 and via email at investorrelations@axogeninc.com. Learn More on Gregory Gene Freitag's contact information.

Has Gregory Gene Freitag been buying or selling shares of AxoGen?

Gregory Gene Freitag has not been actively trading shares of AxoGen within the last three months. Most recently, Gregory Gene Freitag sold 25,000 shares of the business's stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $9.00, for a transaction totalling $225,000.00. Following the completion of the sale, the director now directly owns 271,594 shares of the company's stock, valued at $2,444,346. Learn More on Gregory Gene Freitag's trading history.

Who are AxoGen's active insiders?

AxoGen's insider roster includes P Burke (Director), Erick Devinney (Insider), Michael Donovan (VP), Gregory Freitag (Director), Peter Mariani (CFO), Maria Martinez (Insider), Guido Neels (Director), Joseph Tyndall (Director), Amy Wendell (Director), and Karen Zaderej (CEO). Learn More on AxoGen's active insiders.

Are insiders buying or selling shares of AxoGen?

In the last twelve months, insiders at the medical equipment provider sold shares 3 times. They sold a total of 40,173 shares worth more than $589,236.90. The most recent insider tranaction occured on May, 22nd when Director Joseph A Tyndall sold 20,062 shares worth more than $224,694.40. Insiders at AxoGen own 2.8% of the company. Learn More about insider trades at AxoGen.

Information on this page was last updated on 5/22/2025.

Gregory Gene Freitag Insider Trading History at AxoGen

See Full Table

Gregory Gene Freitag Buying and Selling Activity at AxoGen

This chart shows Gregory Gene Freitag's buying and selling at AxoGen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

AxoGen Company Overview

AxoGen logo
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
Read More

Today's Range

Now: $10.59
Low: $10.46
High: $11.04

50 Day Range

MA: $14.05
Low: $10.80
High: $17.69

2 Week Range

Now: $10.59
Low: $6.59
High: $21.00

Volume

388,628 shs

Average Volume

559,874 shs

Market Capitalization

$482.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05